
|Articles|March 1, 2007
Preliminary evidence shows ranibizumab benefit in DME
Las Vegas-A pilot study of ranibizumab (Lucentis, Genentech), a vascular endothelial growth factor (VEGF) antagonist, showed that the drug has a biological effect in diabetic macular edema (DME), reported Peter Campochiaro, MD, who spoke at the American Academy of Ophthalmology annual meeting.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
2
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)
5





















